The Heart Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Heart Failure Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market.
Some of the key takeaways from the Heart Failure Pipeline Report:
- Companies across the globe are diligently working toward developing novel Heart Failure treatment therapies with a considerable amount of success over the years.
- Heart Failure companies working in the treatment market are Rivus Pharmaceutical, Palatin Technologies, AstraZeneca, Mesoblast, Bayer, Eli Lilly and Company, GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics, Heartseed Inc., Sardocor Corp., Help Therapeutics, Bristol Myers Squibb, and others, are developing therapies for the Heart Failure treatment
- Emerging Heart Failure therapies such as – HU 6, PL 3994, AZD9977, Rexlemestrocel-L, Finerenone, Tirzepatide, GSK3884464, LY 3461767, JK07, HS-001, SRD-001, hiPSC-CM therapy, Mavacamten, and others are expected to have a significant impact on the Heart Failure market in the coming years.
- In February 2023, Mesoblast Limited announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed journal for cardiovascular medicine, the Journal of the American College of Cardiology (JACC)
- In February 2022 Omecamtiv Mecarbil, a selective cardiac myosin activator that is beneficial in enhancing contractility related to heart failure, had its NDA approved by the FDA. Semaglutide, tirzepatide, cimlanod, CardiAMP cell therapy, Revascor (Rexlemestrocel-L), Furoscix infusor, and others are clinical trial medications for CHF. It is anticipated that the approval and subsequent release of such medications will accelerate the expansion of the market
- In June 2019, The Food and Drug Administration (FDA) granted Orphan Drug designation to Revascor (rexlemestrocel-L; Mesoblast), a potential therapy for the prevention of post-implantation mucosal bleedingin end-stage chronic heart failure patients who require a left ventricular assist device (LVAD)
Heart Failure Overview
Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function.
Get a Free Sample PDF Report to know more about Heart Failure Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight
Emerging Heart Failure Drugs Under Different Phases of Clinical Development Include:
- HU 6: Rivus Pharmaceutical
- PL 3994: Palatin Technologies
- AZD9977: AstraZeneca
- Rexlemestrocel-L: Mesoblast
- Finerenone: Bayer
- Tirzepatide: Eli Lilly and Company
- GSK3884464: GlaxoSmithKline
- LY 3461767: Eli Lilly and Company
- JK07: Salubris Biotherapeutics
- HS-001: Heartseed Inc
- SRD-001: Sardocor Corp.
- hiPSC-CM therapy: Help Therapeutics
- Mavacamten: Bristol Myers Squibb
Route of Administration
Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Heart Failure Pipeline Therapeutics Assessment
- Heart Failure Assessment by Product Type
- Heart Failure By Stage and Product Type
- Heart Failure Assessment by Route of Administration
- Heart Failure By Stage and Route of Administration
- Heart Failure Assessment by Molecule Type
- Heart Failure by Stage and Molecule Type
DelveInsight’s Heart Failure Report covers around 90+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Heart Failure product details are provided in the report. Download the Heart Failure pipeline report to learn more about the emerging Heart Failure therapies
Some of the key companies in the Heart Failure Therapeutics Market include:
Key companies developing therapies for Heart Failure are – Bayer AG, Novartis AG, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim International GmbH, Pfizer, Inc., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Novo Nordisk A/S, and others.
Heart Failure Pipeline Analysis:
The Heart Failure pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Heart Failure with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.
- Heart Failure key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Heart Failure drugs and therapies
Heart Failure Pipeline Market Drivers
- Biomarkers helps in understanding the complexity of heart failure, recent advancements in research and development, rising geriatric population are some of the important factors that are fueling the Heart Failure Market.
Heart Failure Pipeline Market Barriers
- However, lack of therapies for HFpEF and acute heart failure, high annual cost, long time duration to measure the Clinical trial endpoints and other factors are creating obstacles in the Heart Failure Market growth.
Scope of Heart Failure Pipeline Drug Insight
- Coverage: Global
- Key Heart Failure Companies: Rivus Pharmaceutical, Palatin Technologies, AstraZeneca, Mesoblast, Bayer, Eli Lilly and Company, GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics, Heartseed Inc., Sardocor Corp., Help Therapeutics, Bristol Myers Squibb, and others
- Key Heart Failure Therapies: HU 6, PL 3994, AZD9977, Rexlemestrocel-L, Finerenone, Tirzepatide, GSK3884464, LY 3461767, JK07, HS-001, SRD-001, hiPSC-CM therapy, Mavacamten, and others
- Heart Failure Therapeutic Assessment: Heart Failure current marketed and Heart Failure emerging therapies
- Heart Failure Market Dynamics: Heart Failure market drivers and Heart Failure market barriers
Request for Sample PDF Report for Heart Failure Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Heart Failure Report Introduction |
|
2 |
Heart Failure Executive Summary |
|
3 |
Heart Failure Overview |
|
4 |
Heart Failure- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Heart Failure Pipeline Therapeutics |
|
6 |
Heart Failure Late Stage Products (Phase II/III) |
|
7 |
Heart Failure Mid Stage Products (Phase II) |
|
8 |
Heart Failure Early Stage Products (Phase I) |
|
9 |
Heart Failure Preclinical Stage Products |
|
10 |
Heart Failure Therapeutics Assessment |
|
11 |
Heart Failure Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Heart Failure Key Companies |
|
14 |
Heart Failure Key Products |
|
15 |
Heart Failure Unmet Needs |
|
16 |
Heart Failure Market Drivers and Barriers |
|
17 |
Heart Failure Future Perspectives and Conclusion |
|
18 |
Heart Failure Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services